Stockpolly
Search
Delisting risk
BOLT · NASDAQ · Biotechnology

Bolt Biotherapeutics (BOLT)

Develops Boltbody immune-stimulating antibody conjugates for cancer.

$3.84
At close−0.23 (−5.65%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue325110122300
Cost of revenue1516015140000000
Gross profit−12−145−14−130122300
66228415131110878
Research & development1516161514111077555
666544443332
General & administrative666540443332
Other expenses−15−160−12−140000001
Operating income−18−20−17−23−16−16−12−9−8−6−8−8
226110111−101
Interest income222111110000
Other non-operating income0−2−6−4−10−1−1−110−1
Income before tax−16−18−11−21−15−16−11−9−7−7−7−8
Net income from continuing operations−16−18−11−21−15−16−11−9−7−7−7−8
Net income−16−18−11−21−15−16−11−9−7−7−7−8
EPS, basic−$0.43−$0.47−$0.28−$0.56−$0.40−$0.42−$0.29−$4.46−$3.72−$3.84−$3.87−$4.57
EPS, diluted−$0.43−$0.47−$0.28−$0.56−$0.40−$0.42−$0.29−$4.46−$3.72−$3.84−$3.87−$4.57
Weighted average shares, basic38——————22222
Weighted average shares, diluted38——————22222
EBITDA−18−17−10−19−15−16−11−8−7−6−7−8
Depreciation & amortization000000000000
EBIT−18−18−11−19−15−16−11−9−7−7−7−8